BiotechTube

PBGENE-HBV

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HEPATITIS B CHRONIC

Conditions

HEPATITIS B CHRONIC

Trial Timeline

Nov 14, 2024 → Dec 1, 2026

NCT ID
NCT06680232

About PBGENE-HBV

PBGENE-HBV is a phase 1 stage product being developed by Precision BioSciences for HEPATITIS B CHRONIC. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06680232. Target conditions include HEPATITIS B CHRONIC.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT07254208Pre-clinicalRecruiting
NCT06680232Phase 1Recruiting

Competing Products

20 competing products in HEPATITIS B CHRONIC

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
85
peginterferon alfa-2a + rivavirinChugai PharmaceuticalPhase 3
77
SOF + COPEChugai PharmaceuticalPre-clinical
23
Colesevelam HclDaiichi SankyoPhase 2
52
ASP9831 + PlaceboAstellas PharmaPhase 2
52
FK788Astellas PharmaPhase 2
52
MK-2248MerckPhase 1
33
Interferon alfacon-1Astellas PharmaPhase 3
77
Pegylated Interferon + RibavirinAstellas PharmaApproved
85
Tacrolimus + steroids, monoclonal anti-IL2R antibodyAstellas PharmaPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Dolutegravir + MethadoneShionogiPhase 1
33
Clevudine + AdefovirEisaiPhase 3
77

Other Products from Precision BioSciences

PBGENE-DMD (IV)Phase 1/2
33
Fludarabine + CyclophosphamidePhase 1/2
33
Fludarabine + Cyclophosphamide + NirogacestatPhase 1
25
PBGENE-HBVPre-clinical
15